KRYSTAL-1: Follow-Up Data on Adagrasib Monotherapy in Patients with Advanced/Metastatic KRASG12C Mutated NSCLC

Opinion
Video

Dr Narjust Florez discusses the KRYSTAL-1 trial, focusing on the effectiveness and side effects of adagrasib in treating patients with NSCLC and KRASG12C mutations, and noting their impact on progression-free and overall survival.

Recent Videos
The 2 main pafolacianine components, a folate analog and a dye, are commonly used in other medical applications.
An intravenous infusion administered prior to surgery enables treatment to occur in a normal time frame without the need for additional procedural time.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Related Content
Data from the phase 3 eXalt3 trial support the approval of ensartinib in adult patients with metastatic ALK-positive non–small cell lung cancer.

FDA Approves Ensartinib in Metastatic ALK-Positive NSCLC

Roman Fabbricatore
December 18th 2024
Article

Data from the phase 3 eXalt3 trial support the approval of ensartinib in adult patients with metastatic ALK-positive non–small cell lung cancer.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials

Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials

Clayton K. Oakley, DO, MS, MA;Amulya Yellala, MD;Sunil Tulpule, MD;Robin High, MA;Apar Kishor Ganti, MD;Alissa S. Marr, MD
December 5th 2024
Article

These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

Richard Lazzaro, MD
April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Sacituzumab Tirumotecan Granted Breakthrough Therapy Designation for NSCLC

Sacituzumab Tirumotecan Granted Breakthrough Therapy Designation for NSCLC

Tim Cortese
December 4th 2024
Article

For patients with EGFR-mutated non–small cell lung cancer, sacituzumab tirumotecan was given the breakthrough drug designation by the FDA.

Despite gaps in biomarker testing accessibility, the lung cancer survival rate has improved by 26% over the last 5 years.

Lung Cancer Survival Improves Despite Biomarker Testing and Screening Gaps

Roman Fabbricatore
November 27th 2024
Article

Despite gaps in biomarker testing accessibility, the lung cancer survival rate has improved by 26% over the last 5 years.